Approx. 17% Early Move for (APRE)—Announces Trial Enrollment Milestone—You Watching?

*Sponsored Market Crux Announces Aprea Therapeutics (Nasdaq: APRE) As Our Next Potential Breakout Idea—For Monday, March 31, 2025! And Here’s Why… Analyst Coverage: HC Wainwright & Co.’s $20 Target On (APRE) Suggests Over 856% Upside Potential. Limited Float: (APRE) Has Less Than 5M Shares In Its Float—Setting the Stage For Significant Swing Potential if Demand Begins to Shift.  Under The Radar: With A Market Cap Under $12M, (APRE) Could be On the Cusp of Major Growth Potential. Consider Taking A Look At Aprea Therapeutics (Nasdaq: APRE)  While It’s Still Early… March 31, 2025 Dear Reader, Have you pulled up (APRE) this morning? Aprea Therapeutics (Nasdaq: APRE) just announced it has dosed the first patient with HPV+ head and neck cancer in its ongoing ACESOT-1051 trial—marking a meaningful step forward for its lead WEE1 inhibitor, APR-1051. This expansion focuses on cancer types that may be especially responsive to the treatment, with open-label data expected later this year. Meanwhile, (APRE) is showing signs of early momentum—moving approximately 17% in the early session, hitting $2.37 and breaking above several key levels, including its 5-Day ($2.20) and 20-Day ($2.35) averages. With its 50, 100, and 200-Day at $3.03, $3.22, and $3.40 respectively, we have all eyes on (APRE) right now. If you missed my earlier coverage, keep reading to see why we’re so excited about (APRE) this morning. Biopharma and biotech remain among the few spaces where a single breakthrough can catapult a company into the spotlight—and Aprea Therapeutics (Nasdaq: APRE) is making the kind of moves that deserve a closer look. With cutting-edge work in synthetic lethality and a focus on precision oncology, Aprea isn’t just following the script—it’s aiming to change the way we fight cancer. But don’t just take our word for it—in a report published last Friday, March 28, 2025, Jason McCarthy, Ph.D., a Senior Managing Director and Head of Biotechnology Research at Maxim Group listed (APRE) with a $16 target. Which suggests over 665% upside potential from Friday’s $2.09 close. And he’s not the only one with a bullish take on (APRE). Benzinga reports that HC Wainwright & Co., one of the country's oldest and most trusted institutions, reiterated a $20 target on (APRE), which suggests over 856% upside potential from Friday’s close. Why Aprea Therapeutics (Nasdaq: APRE) Is Flying Under the Radar… While large-cap companies may dominate the headlines, it’s often the small and micro-caps that offer the greatest growth potential.  With leaner operations, smaller revenue bases, and the ability to pivot quickly, these companies can scale rapidly when the right catalyst hits. Take Aprea Therapeutics (Nasdaq: APRE)—with a market cap under $12M and fewer than 5M shares in the float, this is a company operating with the kind of tight structure that has historically fueled explosive growth potential. Keep reading to see why Aprea Therapeutics (Nasdaq: APRE) is topping our watchlist this morning… (Monday, 3/31/2025) Not Just Another Biotech—Here’s What Sets Aprea Therapeutics (Nasdaq: APRE) Apart… Let’s cut straight to the chase: Aprea Therapeutics (Nasdaq: APRE) isn’t simply following the usual biotech script.  Rather, they're pursuing groundbreaking approaches with therapies that specifically target some of cancer’s most stubborn forms. These treatments aren’t incremental improvements—they could fundamentally alter how cancer care is delivered, potentially improving outcomes where current methods fall short. If you're interested in discovering a biotech firm with genuine vision and the capability to disrupt the traditional cancer treatment landscape, Aprea Therapeutics might just deserve your attention. Aprea Therapeutics (Nasdaq: APRE) Is Setting Its Sights on Major Oncology Breakthroughs… While many biotech companies are merely trying to keep pace, Aprea Therapeutics is forging ahead with therapies designed to tackle challenging cancers through a concept called synthetic lethality. Instead of broad-spectrum, traditional treatments, they're developing highly selective therapies that target cancer cells' genetic vulnerabilities, potentially leading to fewer side effects and more effective outcomes. With several clinical milestones approaching, including significant data readouts, Aprea Therapeutics (Nasdaq: APRE) is demonstrating proactive leadership that positions it as one little-known company to keep a close eye on. What Exactly Is Aprea Doing? Aprea Therapeutics (Nasdaq: APRE) is in the business of precision oncology, and not in the "here’s a generic treatment" way.  They’re pioneers in a groundbreaking concept called synthetic lethality.  This isn’t just some buzzword thrown around by your typical biotech firm; this is a targeted approach that could actually make cancer treatments more effective and less toxic.  Their mission?  To stop tumors in their tracks by exploiting the very weaknesses in cancer cells that make them so dangerous. In addition to their groundbreaking therapies, Aprea Therapeutics (Nasdaq: APRE) has strengthened its position with a strategic evolution in its intellectual property (IP) portfolio.  This patent portfolio reflects their commitment to securing long-term value for their cutting-edge treatments.  The ATR inhibitor program is now protected by a strong estate, including four granted U.S. patents, 19 granted non-U.S. patents, and 16 pending applications, extending exclusivity through 2044.  This IP foundation is key for protecting the value of their assets as they advance treatments like ATRN-119 and APR-1051, which are currently in clinical trials targeting DDR-related mutations. They’re going after two major targets in the DNA Damage Response (DDR) system: ATR and WEE1.  These are not your everyday targets—these are the type of molecules that could make or break the future of cancer treatments. Why Aprea Therapeutics (Nasdaq: APRE)’s Pipeline Is Turning  Heads in the DDR Space… Aprea Therapeutics (Nasdaq: APRE) is making significant strides in the fight against cancer, with two potentially best-in-class inhibitors that could disrupt current cancer care. ATRN-119 Aprea Therapeutics (Nasdaq: APRE)’s ATRN-119 is a macrocyclic ATR inhibitor, and it stands out in a major way.  Unlike first-generation ATR inhibitors, which have been associated with serious toxicity and inconsistent dosing schedules, ATRN-119 has been engineered to be selective and highly potent.  This means patients could experience less toxicity, more effective continuous dosing, and a smoother treatment process overall.  In preclinical studies, ATRN-119 has shown strong tumor control, including in some of the most challenging genetic backgrounds.  This makes it a potential game-changer in the oncology space. APR-1051 If you’ve been following oncology, you’ve likely heard of WEE1 inhibitors.  But APR-1051 is different.  This inhibitor is structurally differentiated and demonstrates high selectivity.  Unlike other treatments that often disrupt multiple systems—leading to toxic side effects—APR-1051 is more targeted, focusing specifically on its cancer-related proteins while leaving healthy cells largely unaffected.  Early studies suggest that APR-1051 could suppress tumors without the typical hematologic toxicity (blood-related side effects) that often accompanies cancer treatments.  It shows strong potential for anti-tumor activity, especially in cancers with CCNE1 amplification—for example, ovarian cancer. Aprea Therapeutics (Nasdaq: APRE) Moves Aggressively With Next-Phase ATRN-119 Dosing… Aprea Therapeutics (Nasdaq: APRE)’s Cancer Breakthroughs Are Accelerating… Aprea Therapeutics (Nasdaq: APRE) just announced fresh momentum across its two lead programs: -APR-1051 (WEE1 inhibitor) is now enrolling Cohort 5 with no blood-related side effects to date—open-label efficacy data expected H2 2025. -ATRN-119 (first-in-class ATR inhibitor) now in twice-daily dosing to maximize tumor control, with dose escalation wrapping up later this year. -Backed by $22.8M in ca-sh and new clinical leadership, Aprea is advancing fast. Get the full story before the next phase kicks in. 7 Reasons Why Aprea Therapeutics (Nasdaq: APRE) is Topping Our Watchlist This Morning… 1. Under The Radar: With a market cap under $12M and fewer than 5M shares in the float, (APRE) has the kind of structural setup that historically has shown the potential for significant moves if demand begins to shift.  2. Analyst Coverage: HC Wainwright & Co. maintains a $20 target, suggesting over 856% upside potential from Friday’s $2.09 close—while Maxim Group set a $16 target.  3. Strong Fiscal Position: As of year-end 2024, Aprea reported $22.8M in ca-sh, giving it the runway to continue advancing key programs through upcoming milestones. 4. Disruptive Cancer Research: The company is advancing ATRN-119 and APR-1051—two therapies focused on DDR-related mutations, a target area with urgent need and limited options. 5. Innovative Dosing Strategy: A new twice-daily regimen for ATRN-119 is designed to maintain 24-hour target coverage—an approach that may enhance impact in ongoing clinical trials. 6. First-in-Class Advantage: ATRN-119 is the first macrocyclic ATR inhibitor in human trials, engineered for selectivity and potency—setting it apart from older, less targeted approaches. 7. Encouraging Early Data: Preclinical signals show ATRN-119 delivering strong tumor control, while APR-1051 continues enrolling with no blood-related side effects observed to date—key safety data is expected in H2 2025. Consider Adding Aprea Therapeutics (Nasdaq: APRE) To Your  Radar While It’s Still Early… Aprea Therapeutics (Nasdaq: APRE) is a little-known company with strong upside potential, as indicated by HC Wainwright & Co.’s $20 target—which suggests 856% upside potential.  With a market cap under $12M and fewer than 5M shares in the float, (APRE) has significant growth potential, especially given its $22.8M in ca-sh. The company is leading the way with ATRN-119 and APR-1051, two innovative therapies targeting DDR-related mutations that may offer a differentiated approach that addresses unmet needs in cancer care. The shift to a twice-daily dosing regimen for ATRN-119 enhances its efficacy, while its first-in-class status and promising preclinical data give (APRE) a competitive edge in oncology. We have (APRE) at the top of our screens right now. Now’s the time to pull up (APRE) if you haven’t done so yet. Consider taking a look at (APRE) while it’s still early and before it gets any later. (APRE) moved approximately 17% in the early session, reaching $2.37, while surpassing several key moving averages, including its 5-Day at $2.20 and 20-Day at $2.35. If you have not done so yet, now could be the best time to pull up (APRE) and start your research. I’ll check back in with you shortly—so keep an eye out for my next update. Sincerely, Gary Silver Managing Editor, MarketCrux MarketCrux.com (“MarketCrux” or “MC” ) is owned by Headline Media LLC, a multi member limited liability company. Data is provided from third-party sources and MarketCrux is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MC brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in.vest.ment advice, are not in.vest.ment advisors, and any profiles we mention are not suitable for all in.vest.ors. The owners of Headline Media LLC own and operate marketcrux . com (“MC”). From time to time, MC will publicly disseminate information about a company via website, email, SMS and other points of media. Please see important disclosure information here: marketcrux.com/disclaimer/  *Pursuant to an agreement between Headline Media LLC and TD Media LLC, Headline Media LLC has been hired for a period beginning on 03/30/2025 and ending on 03/31/2025 to publicly disseminate information about (APRE:US) via digital communications. Under this agreement, Headline Media LLC has been paid seven thousand five hundred USD (“Funds”). To date, including under the previously described agreement, Headline Media LLC has been paid fifteen thousand USD (“Funds”). These Funds were part of the funds that TD Media LLC received from a third party who did receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither Headline Media LLC, TD Media LLC and their member own shares of (APRE:US). Please see important disclosure information here: https://marketcrux.com/disclosure/apre/#details

Headline Media | 7901 4th Street N Suite 300 | St. Petersburg, FL 33702 US Unsubscribe | Update Profile | Constant Contact Data Notice